In Vitro Modelling
Bioneer has extensive experience in developing advanced in vitro models and assays that replicate cellular or molecular aspects of diseases and in vivo conditions.
By leveraging state-of-the-art tools and technologies, such as human induced pluripotent stem cells (iPSCs), which can be differentiated into neuronal or immune cell types, alongside CRISPR genome engineering and high-content image analysis, we can generate high-quality data for your innovative CNS, immunology, or oncology projects. Our specialized BioSPHEER™ Advanced 3D Cancer Modelling Platform offers a range of pre-validated tumor models or can be custom-designed to assess your drug candidates, regardless of the drug modality.
Additionally, our gastric modelling services, utilizing the proprietary Dynamic Gastric Model (DGM) or our cell-based assays, enable comprehensive bioequivalence and permeability studies for your drug formulation.
Whether you represent a pharmaceutical company, a biotech firm, or an academic institution, we provide custom research solutions tailored to your specific needs.
Our services provide you with unique insights to target validation, lead evaluation, biomarker discovery, molecular profiling, bioavailability, and mode of action studies.
Our diverse team of scientists bring years of experience and an in-depth understanding of disease modelling to every project that can help you advance your drug discovery programs within:
Cancer and Immuno-Oncology
Bioneer is dedicated to creating innovative and comprehensive research solutions and tools for developing novel and effective treatments against cancer.
To support the early development of cancer therapeutics, Bioneer offers a range of human in vitro cancer models tailored for evaluating different drug modalities.
With a particular focus on development of cancer drugs targeting solid tumours (e.g. breast, colon and pancreatic cancer) we have developed novel multicellular BioSPHEER ™ 3D cancer models with unique architectural organization.
These novel BioSPHEER™ models are co-cultures with fibroblast cells, which support solid tumor-like spheroid formation and enable immune cell infiltration of the spheroids.
Together these features provide a more translatable tool compared to traditional models by creating an in vivo-like solid tumor microenvironment, making 3D models a valuable tool for both target validation and lead evaluation.
Our state-of-the-art technology platforms and supplementary methodologies generate data for the development and evaluation of different drug modalities including e.g. small molecules, peptides, therapeutic antibodies, gene and cell-based therapies.
To support the early development of cancer therapeutics, Bioneer offers a range of human in vitro cancer models tailored for evaluating different drug modalities.
With a particular focus on development of cancer drugs targeting solid tumours (e.g. breast, colon and pancreatic cancer) we have developed novel multicellular BioSPHEER ™ 3D cancer models with unique architectural organization.
These novel BioSPHEER™ models are co-cultures with fibroblast cells, which support solid tumor-like spheroid formation and enable immune cell infiltration of the spheroids.
Together these features provide a more translatable tool compared to traditional models by creating an in vivo-like solid tumor microenvironment, making 3D models a valuable tool for both target validation and lead evaluation.
Our state-of-the-art technology platforms and supplementary methodologies generate data for the development and evaluation of different drug modalities including e.g. small molecules, peptides, therapeutic antibodies, gene and cell-based therapies.
Immunology
We provide a broad range of services, support and custom-made assays within immunology, at all levels from basic research and early discovery to clinical sample evaluation.
Whether you are exploring novel immunotherapies, working with immune-oncology, investigating immune responses to pathogens, or unraveling the complexities of autoimmune diseases, we are here to support your endeavors. From biomarker discovery to immune profiling, our customizable solutions provide key insights and drive impactful discoveries about the potential of your drug candidates.
Our long-standing experience in immunology has been the key driver to establish a broad range of high quality in vitro immune model assays.
Whether you are exploring novel immunotherapies, working with immune-oncology, investigating immune responses to pathogens, or unraveling the complexities of autoimmune diseases, we are here to support your endeavors. From biomarker discovery to immune profiling, our customizable solutions provide key insights and drive impactful discoveries about the potential of your drug candidates.
Our long-standing experience in immunology has been the key driver to establish a broad range of high quality in vitro immune model assays.
Central Nervous System
Your CNS drug discovery partner
Developing new CNS therapies requires a deep understanding of disease biology and a partner who can translate scientific questions into meaningful drug discovery strategies.
At Bioneer, we combine expertise in CNS biology with advanced cellular engineering, assay development, and human iPSC-based disease models to support preclinical drug discovery.
From target validation and disease modelling to compound screening and mechanistic studies, we help generate robust, biologically relevant data needed to move promising drug candidates forward.
Our scientists work as an extension of your team, combining biological insight with flexible experimental design to build models and assays tailored to your research questions.
Whether your focus is neurodegeneration, neuroinflammation, pain, or other CNS indications, we help de-risk discovery programs through collaborative science and human-relevant in vitro systems.
The challenge of translating CNS research into therapies
Developing therapies for CNS disorders remains challenging because conventional preclinical models often fail to recapitulate key aspects of human disease biology
As a result, promising drug candidates often fail when moving from preclinical research into clinical development.
At Bioneer, our deep understanding of CNS disease biology shapes the way we develop human-relevant cellular models and assays that reflect the underlying disease mechanisms.
By combining biological insight with advanced in vitro systems, we help generate more predictive data to support informed decision-making throughout drug discovery.
Our services within CNS
We provide integrated capabilities that support every stage of preclinical CNS drug discovery, helping you generate biologically relevant data and move promising drug candidates forward.
100+ Publications in CNS research
Bioneer has over 100 publications in CNS research, including collaborations with Novo Nordisk, Lundbeck, UCB Biopharma, Pfizer Ltd, AstraZeneca, Eli Lilly and Johnson & Johnson.
From target validation and disease modelling to compound screening and mechanistic studies, we help generate robust, biologically relevant data needed to move promising drug candidates forward.
Our scientists work as an extension of your team, combining biological insight with flexible experimental design to build models and assays tailored to your research questions.
Whether your focus is neurodegeneration, neuroinflammation, pain, or other CNS indications, we help de-risk discovery programs through collaborative science and human-relevant in vitro systems.
The challenge of translating CNS research into therapies
Developing therapies for CNS disorders remains challenging because conventional preclinical models often fail to recapitulate key aspects of human disease biology
As a result, promising drug candidates often fail when moving from preclinical research into clinical development.
At Bioneer, our deep understanding of CNS disease biology shapes the way we develop human-relevant cellular models and assays that reflect the underlying disease mechanisms.
By combining biological insight with advanced in vitro systems, we help generate more predictive data to support informed decision-making throughout drug discovery.
Our services within CNS
We provide integrated capabilities that support every stage of preclinical CNS drug discovery, helping you generate biologically relevant data and move promising drug candidates forward.
Explore our capabilities below
100+ Publications in CNS research
Bioneer has over 100 publications in CNS research, including collaborations with Novo Nordisk, Lundbeck, UCB Biopharma, Pfizer Ltd, AstraZeneca, Eli Lilly and Johnson & Johnson.
Contact us for a free consultation
Interested in learning how we can support your project or pipeline?
We´re always happy to chat.
For further information please contact Business Development Manager Jacob Mathias Bech on jmb@bioneer.dk or +4523202576
For further information please contact Business Development Manager Jacob Mathias Bech on jmb@bioneer.dk or +4523202576
